This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.

This book examines applications of multi-omics approaches for understanding disease etiology, pathogenesis, host-pathogen interactions. It also analyzes the genetics, immunological and metabolic mechanisms underlying the infections. The book also explores genomics, transcriptomics, translational-omics, and metabolomics approaches to understand the pathogenesis and identify potential drug targets. It reviews the role of epigenetic reprogramming in shaping the host-pathogen interactions and presents bioinformatics application in the identification of drug targets. Further, it examines the potential applications of RNA sequencing and non-coding RNA profiling to identify the pathogenesis. Lastly, it offers the current challenges, technological advances, and prospects of using multi-omics technologies in infectious biology.

The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.

The modus operandi of salivary proteins in reducing the kinetics of hydroxyapatite and enamel dissolution during simulated caries challenges is thought to be associated with interaction of glutamic acid residues with hydroxyapatite (HAp)surfaces. Polygamma glutamic acid (PGGA) is the basis of theJapanese traditional foodstuff 'Natto' and is a naturally occurring polypeptide composed of glutamic acid residues, and may therefore perform simlar caries inhibitory functions.

Tuberculosis (TB) has been reported to have fifth highest fatality rate in the world, a disease claiming between 2 and 3 million lives a year. One of the important reasons why this killer parasite is spiraling out of control at an alarming rate is attributed to the prevalence of multidrug-resistant (MDR) strains and emergence of AIDS-related TB. Focus has now been shifted towards development of compounds from natural sources that have antimycobacterial activity. The incorporation of such compounds, like polyphenols namely Epigallocatechin-3-gallate (EGCG) from green tea, as the natural component of tuberculosis treatments has been studied here. Reactive oxygen species and tumor necrosis factor (TNF- ) are the hallmarks of tuberculosis. The augmented expression of TNF- at both the gene and protein levels in MTB-infected monocytes is suppressed by EGCG in dose-dependent manner. Also, EGCG ameliorated the IFN- levels, the glutathione peroxidase activity, which correlated inversely with the downregulation of ROS and TNF- in MTB-infected monocytes. Hence, EGCG may prove to be a valuable natural antioxidant in tuberculosis management."